logo
Inflammation is a 'double-edged sword': How to protect against chronic disease

Inflammation is a 'double-edged sword': How to protect against chronic disease

Yahoo04-03-2025

Why do our ankles swell when they're sprained or does our skin turn red — or inflamed — when it's scraped?
That quick response is caused by inflammation — and it can save your life.
At its core, inflammation is the 'response of the body to an illness or an injury to try to restore health,' said Dr. Robert Shmerling, a rheumatologist and faculty member at Harvard Medical School who helped author a report on inflammation.
Inflammation has come under fire for its link to a variety of chronic diseases, including diabetes, heart disease and even allergies. Longevity experts even see reducing chronic inflammation as key to healthier aging.
'It's a classic double-edged sword,' said Dr. David Hafler, a neurologist and professor of immunobiology at Yale School of Medicine.
Inflammation is necessary for survival, and without it our bodies wouldn't be able to fight off intruders like viruses and bacteria. A sore throat, for example, turns red and is painful because the immune system is fighting the infection to prevent it from spreading, which doctors call acute inflammation, said Dr. Moshe Arditi, a pediatrician and director of the infectious and immunological diseases research center at Cedars-Sinai Medical Center in Los Angeles.
'Localized immune response in the acute stage — to a limited extent — is all beneficial inflammation,' he said.
The discovery of inflammation dates back centuries to the Roman encyclopedist Aulus Cornelius Celcus, one of the first people to define it. Celcus described the core signs of inflammation in Latin as rubor, tumor, calore, delore. The terms translate to redness, swelling, heat and pain, which still hold true.
At a microscopic level, acute inflammation includes our bodies' sending fluid, proteins and white blood cells to the sites of infections or injuries, which help fight foreign pathogens and promote healing.
While inflammation can be lifesaving in the short term, there is another type of inflammation, chronic inflammation, that can damage the body over the long term.
Several risk factors make your body more likely to have chronic inflammation — including obesity, which promotes a low-level inflammatory state throughout the body, tobacco smoking and diet.
Dr. Thaddeus Stappenbeck, chair of inflammation and immunity at the Cleveland Clinic, suspects the modern American diet is a major source of chronic inflammation.
Processed foods, refined sugars, trans fats and excessive consumption of red meat are associated with increased inflammation. The Food and Drug Administration banned trans fats in 2015, and they were finally removed from snacks, bread, cookies and other baked goods in 2018.
'I suspect that there's more people with underlying, chronic inflammation than there were in the past,' Stappenbeck said. 'I think about the way we've shifted our diet where we eat a lot of chemicals that we are not adapted to consume, and these have a number of effects on our intestines.'
Shmerling said, 'Lack of exercise, lack of sleep, too much stress, all of those are lifestyle factors associated that are pro-inflammatory.'
Signs may vary, but they include:
Joint pain that doesn't improve.
Fatigue.
Constipation
Depression.
Weight loss, regular exercise and avoiding highly processed foods can reduce levels of inflammation in the body, Shmerling said. Studies have suggested that following a Mediterranean diet, largely plant-based with an emphasis on whole fruits and vegetables, can reduce levels of inflammation.
'It's often not an on/off kind of switch,' he said. 'We don't have perfect ways to measure inflammation after making a lifestyle modification, but inflammatory markers can improve with lifestyle changes.'
An estimated 129 million people in the United States have at least one chronic disease, according to the Centers for Disease Control and Prevention. The prevalence of chronic disease has grown by about 7 million people every five years, according to estimates from Stanford University.
The causes of chronic disease are complicated, but experts are increasingly convinced that inflammation is playing a role.
'There's a fair amount of consensus that a lot of the chronic diseases we see now in higher prevalence than in the past could well be related to chronic inflammation,' Shmerling said.
What comes first — the inflammation or the disease? When the body is in an inflammatory state, it can start to destroy the very things it needs to function, such as our vital organs and blood vessels.
'Ongoing inflammation may lead to heart disease and building of plaque in the blood vessels, which can lead to heart attack and strokes," said Arditi, of Cedars-Sinai. 'Long-term inflammation in your brain may lead to development of neurodegenerative diseases by damaging neurons and interfering with normal brain function.'
Autoimmune disorders like lupus or multiple sclerosis are also linked to chronic inflammation as the immune system starts to attack various parts of the body in friendly fire.
'The body is not distinguishing properly between itself and an outside intruder or a pathogen,' Shmerling said. 'There's chronic inflammation that's ongoing and quite damaging.'
Diseases including Parkinson's and even diabetes all have inflammatory components to them, Stappenbeck said. Because of inflammation's close relationship to a host of diseases, he's not surprised by patients coming in asking to be checked for it.
'I think there's a desire from patients to say, 'Can you actually detect this in me earlier, before I get super sick?'' he said.
There are blood tests for inflammation, but they aren't perfect. They don't provide clear answers about where the inflammation may be lurking in the body.
There can also be false positives. That's why experts say the tests must be interpreted along with symptoms.
One of the most common tests is called the erythrocyte sedimentation rate, a blood test that measures the level of certain proteins that correlate with the amount of inflammation in the body.
Another test assesses c-reactive protein (CRP), a protein the liver produces in response to inflammation.
Because of the limitations, Shmerling doesn't recommend that healthy people with no symptoms be routinely screened for inflammation.
'There can be normal inflammation tests even when inflammation is present, and sometimes the tests are abnormal even when it doesn't seem there is any inflammation present,' he said. 'So they're not perfect.'
Stappenbeck agreed.
'I don't think there's much of a role for it, actually,' he said.
There is some potential for a test called hs-CRP, a more sensitive test that can find smaller increases in c-reactive protein in the blood. High levels of that protein in the blood have been linked to heart attacks and strokes.
Some argue that this test should be done routinely, just like checking cholesterol, to determine who is more at risk of heart attacks and stroke.
The evidence, however, has been mixed, which is why the test isn't widely performed.
'There are people who are so low-risk or so high-risk that it's very unlikely the CRP is going to help you,' Shmerling said. 'There are subsets of people, maybe at moderate risk, where a CRP for cardiac risk could be helpful.'This article was originally published on NBCNews.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Does a Michelada Without Beer Still Taste as Sweet?
Does a Michelada Without Beer Still Taste as Sweet?

Bloomberg

timean hour ago

  • Bloomberg

Does a Michelada Without Beer Still Taste as Sweet?

I find myself unhappily on trend. Young people everywhere are increasingly 'on the wagon' — to use the American idiom for sobriety from the 1920s, when the 18th Amendment to the US Constitution banned the production and sale of alcohol. The wagon in the expression was a public- service vehicle loaded with water to tamp down dust and grime on city streets; by extension, it described the clean and sober law-abiding citizens of America. According to some estimates, 39% of Gen Z say they have foresworn alcoholic drinks; about half of them imbibe such beverages only occasionally. Many have taken to non-alcoholic alternatives. I didn't set out to join that youthful bandwagon. Nevertheless, I have been alcohol-free since Jan. 20, 2025. Those of you who recognize that date as US Inauguration Day must get the coincidence out of your head. It just happened to be when I felt I'd had too much wine over the previous three months. Alas, my doctors agreed with me — because of decades of loving wine and champagne, not just those recent three months. And so, I've spent nearly 140 days looking at how to enjoy the brave new world of NA — a market that's gotten a huge boost in sales and creativity precisely because of health-focused Gen Z, a cohort that probably makes up 25% of the world's population. I am a late Boomer, but now I'm medically required to be young at heart.

Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Ask the Expert: Should I have Biomarker Testing – and Would it Help?

Health Line

timean hour ago

  • Health Line

Ask the Expert: Should I have Biomarker Testing – and Would it Help?

Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.

Elon Musk trades threats with Trump: What it could mean for SpaceX launches in Florida
Elon Musk trades threats with Trump: What it could mean for SpaceX launches in Florida

Yahoo

time7 hours ago

  • Yahoo

Elon Musk trades threats with Trump: What it could mean for SpaceX launches in Florida

When President Donald Trump took office in January, he began offering plenty of signs that his goals for U.S. spaceflight aligned closely with those of billionaire tech mogul Elon Musk. Now those goals, which included making reaching Mars during Trump's second term a top priority, appear to be up in the air amid an increasingly volatile fallout between two of the world's most powerful men. As insults have turned to threats, Trump has suggested he'd hit Musk where it could hurt most: His wallet. Musk's SpaceX has spent years positioning itself at the center of American civil and military spaceflight – a profitable relationship that has made the company's CEO incredibly wealthy. In response, Musk has floated – and then retracted – the idea of decommissioning a SpaceX vehicle critical to NASA's spaceflight program. The vast majority of SpaceX's missions with NASA and the government launch from Cape Canaveral, either from the space agency's Kennedy Space Center or the Cape Canaveral Space Force Station. Serious threats, or empty words? That remains to be seen as Musk and Trump reportedly consider a détente. In the meantime, here's what to know about what's at stake if the U.S. government's relationship with SpaceX were to crumble: U.S. spaceflight: Trump looks to axe many NASA space missions that launched from Florida The feud between Trump and his former top advisory escalated in a dramatic fashion when the president threatened to cut off the taxpayer dollars that have fueled the growth of SpaceX, of which Musk is the CEO. "The easiest way to save money in our Budget, Billions and Billions of Dollars, is to terminate Elon's Governmental Subsidies and Contracts," Trump said in a post on his social media platform. "I was always surprised that Biden didn't do it!" In all, Musk and his businesses have received at least $38 billion in government contracts, loans, subsidies and tax credits, a Washington Post analysis found. How the potential fallout between two of the world's most powerful men could affect U.S. spaceflight ambitions remains to be seen. NASA Press Secretary Bethany Stevens said in a post on social media site X that 'NASA will continue to execute upon the President's vision for the future of space.' 'We will continue to work with our industry partners to ensure the President's objectives in space are met,' Stevens wrote. Elon Musk, the world's richest man, founded Space Exploration Technologies Corp., more widely known as SpaceX, in 2002. The commercial spaceflight company is headquartered at Starbase in South Texas. The site, which is where SpaceX has been conducting routine flight tests of its 400-foot megarocket known as Starship, was recently voted by residents to become its own city. SpaceX benefits from billions of dollars in contracts from NASA and the Department of Defense, which use many of the company's spacecraft to help launch government missions. SpaceX also conducts many of its own rocket launches, most using the Falcon 9 rocket. That includes a regular cadence of deliveries of Starlink internet satellites into orbit from both California and Florida, and occasional privately-funded commercial crewed missions on the Dragon. SpaceX is also planning to bring its Starship operations to Florida by the end of 2025. The most recent of SpaceX's private human spaceflights, a mission known as Fram2, took place in April. SpaceX was also famously involved in funding and operating the headline-grabbing Polaris Dawn crewed commercial mission in September 2024. SpaceX provides launch services to the Pentagon, including the launch of classified satellites and other payloads. CEO Gwynne Shotwell has said the company has about $22 billion in government contracts, according to Reuters. The vast majority of that, about $15 billion, is derived from NASA. SpaceX's famous two-stage Falcon 9 rocket ‒ one of the world's most active ‒ is routinely the rocket of choice to get many NASA missions off the ground. For instance, the rocket is due in the days ahead to help propel a four-person crew of private astronauts to the International Space Station for a venture with NASA known as Axiom Mission 4. NASA also has plans to use SpaceX's Starship in its Artemis lunar missions to ferry astronauts aboard the Orion capsule from orbit to the moon's surface. The rocket, which is in development, has yet to reach orbit in any of its nine flight tests beginning in April 2023. SpaceX's Dragon capsule is also a famous vehicle that is widely used for a variety of spaceflights. The capsule, which sits atop the Falcon 9 for launches to orbit, is capable of transporting both NASA astronauts and cargo to the space station. Under NASA's commercial crew program, the U.S. space agency has been paying SpaceX for years to conduct routine spaceflights to the International Space Station using the company's own launch vehicles. The first of SpaceX's Crew missions ferrying astronauts to the orbital outpost on the Dragon began in 2020, with the tenth and most recent contingent reaching the station in March for about a six-month stay. Standing nearly 27 feet tall and about 13 feet wide, Dragon capsules can carry up to seven astronauts into orbit, though most of SpaceX's Crew missions feature a crew of four. The Dragon spacecraft also was the vehicle NASA selected to bring home the two NASA astronauts who rode the doomed Boeing Starliner capsule to the space station in June 2024. Certifying the Starliner capsule for operation would give NASA a second vehicle in addition to Dragon for regular spaceflights to orbit. Because Boeing is still developing its Starliner capsule, Dragon is the only U.S. vehicle capable of carrying astronauts to and from the space station. It's also one of four vehicles contracted to transport cargo and other supplies to the orbital laboratory. For that reason, Musk's threat Thursday, June 5 to decommission the Dragon "immediately" would be a severe blow to NASA if he were to follow through on it. Musk, though, appears to already be backing off on the suggestion, which he made in response to Trump's own threats. In response to a user who advised Musk to "Cool off and take a step back for a couple days," Musk replied: 'Good advice. Ok, we won't decommission Dragon.' Seven astronauts are aboard the International Space Station, including three Americans. Four of the astronauts rode a SpaceX Dragon to the station for a mission known as Crew-10, while the remaining three launched on a Russian Soyuz spacecraft. Contributing: Joey Garrison, Josh Meyer, USA TODAY; Reuters Eric Lagatta is the Space Connect reporter for the USA TODAY Network. Reach him at elagatta@ This article originally appeared on Florida Today: SpaceX at center of Trump, Musk feud: What it could mean for Florida

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store